Rhythm Pharmaceuticals, Inc. (RYTM) financial statements (2021 and earlier)

Company profile

Business Address 222 BERKELEY STREET
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:173202229257292162195
Cash and cash equivalents101685956627263
Short-term investments72      
Other undisclosed cash, cash equivalents, and short-term investments 13417020223091132
Other current assets3   4  
Other undisclosed current assets68910688
Total current assets:182210238268302171204
Noncurrent Assets
Operating lease, right-of-use asset2222223
Property, plant and equipment3334444
Other undisclosed noncurrent assets0000010
Total noncurrent assets:5666677
TOTAL ASSETS:187215243274309178211
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17151417242526
Accounts payable54561087
Accrued liabilities13121011141719
Debt  10000
Other undisclosed current liabilities11     
Total current liabilities:18161518242526
Noncurrent Liabilities
Long-term debt and lease obligation333 333
Finance lease, liability333 333
Liabilities, other than long-term debt   3   
Deferred rent credit   3   
Total noncurrent liabilities:3333333
Total liabilities:21191821282829
Stockholders' equity
Stockholders' equity attributable to parent167197226253281149181
Common stock0000000
Additional paid in capital626621616613606441438
Accumulated other comprehensive income001    
Accumulated deficit(459)(424)(391)(359)(325)(292)(256)
Total stockholders' equity:167197226253281149181
TOTAL LIABILITIES AND EQUITY:187215243274309178211

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(35)(34)(32)(35)(34)(37)(44)
Operating loss:(35)(34)(32)(35)(34)(37)(44)
Nonoperating income
(Investment Income, Nonoperating)
0011111
Net loss available to common stockholders, diluted:(35)(34)(31)(34)(33)(36)(43)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(35)(34)(31)(34)(33)(36)(43)
Other undisclosed comprehensive loss    (141)  
Comprehensive loss:(35)(34)(31)(34)(174)(36)(43)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)10   
Comprehensive loss, net of tax, attributable to parent:(35)(34)(31)(34)(174)(36)(43)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: